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Abstract
This literature review aims to evaluate the epidemiologic profile of patients with rheumatoid arthritis (RA) that
developed a bisphosphonate-related osteonecrosis that affect the jaws (BRONJ), including demographic aspects, as
well as clinical and therapeutic issues. A search of PUBMED/MEDLINE, Scopus, and Cochrane databases from
January 2003 to September 2011 was conducted with the objective of identifying publications that contained case
reports regarding oral BRONJ in RA patients. Patients with RA who develop oral BRONJ are usually women above
60 years taking steroids and long-term alendronate. Most of them have osteoporosis, and lesions, triggered by
dental procedures, are usually detected at stage II in the mandible. Although there is no accepted treatment
protocol, these patients seem to have better outcomes with conservative approaches that include antibiotic
therapy, chlorhexidine, and drug discontinuation.
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Background
Bisphosphonates (BPs) are stable synthetic analogs of
inorganic pyrophosphate that suppress osteoclast-
mediated bone resorption [1]. In this way, they have been
widely used to stabilize bone loss in patients with rheu-
matoid arthritis (RA), especially those who develop
osteoporosis, which is a common feature in this rheu-
matic disease [2]. However, since 2003, great concern has
been generated regarding the side-effects of these drugs
through increasing reports, worldwide, of a bisphospho-
nate-related osteonecrosis that affect the jaws (BRONJ).
There are many hypotheses regarding BRONJ pathogen-
esis, but none of them is completely accepted. Although
there have been reports with no obvious co-morbidity fac-
tors [3,4], it is reasonable to believe that co-factors may
play a relevant role in the development of these lesions,
especially in patients taking oral BPs. Among these co-
factors, RA has been included as a relevant risk factor for
BRONJ; however, until now the relationship between
these diseases has not been fully explained.
Due to the greater number of patients taking oral BPs
for the treatment of RA and osteoporosis, it is very
important for risks to be assessed. Thus, the purpose of
this extended literature review is to evaluate relevant
issues of patients with RA who developed oral BRONJ,
including demographic, clinical, and treatment aspects,
with the goal of establishing comparative associations
with patients without RA who developed oral BRONJ.
Methods
We performed a computerized search to identify all papers
published in English from January 2003 to September
2011 in PUBMED/MEDLINE, Scopus, and Cochrane data-
bases. Case reports, case series, and retrospective studies
were included, while short communications and letters to
the Editor were excluded. The studies were approved by
the Ethics in Human Research Committee and were in
compliance with the ethical principles of the Helsinki
Declaration. Literature reviews and systematic reviews also
were considered with the objective of identifying cases
already reported. The key MeSH (Medical Subject
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The primary objective was to identify all articles con-
taining clinical reports with the following inclusion
criteria:
￿ Diagnosis of RA and oral BRONJ
￿ Patients with no prior history of radiation to the cra-
niofacial region
￿ Non-neoplasic patients
￿ At least five areas of the specific demographics were
collected, including gender,a g e ,b i s p h o s p h o n a t et y p e
and length of exposure, concomitant medications, trig-
ger event, clinical features, staging, lesion site, imaging
and histological features, as well as management and
outcomes. The stage of the lesions was retrieved directly
from the papers or it was defined based on the available
clinical data and according to the classification system
by Ruggiero et al. [5].
￿ Papers published in English
All titles and abstracts from the results of the litera-
ture search were reviewed by the authors for potential
inclusion in our study. We also searched the related
links of all relevant papers. Furthermore, all relevant
papers were checked to avoid multiple inclusions of the
same patients in this study.
Results
The search strategy yielded 1606 titles/abstracts from
the databases analyzed. After title, abstract screening,
and/or paper analyses, 331 potentially relevant studies
were identified and screened for retrieval. Of these, 312
studies were excluded due to non-compliance with the
inclusion criteria, one paper was excluded due to dupli-
city of one patient and, finally, 17 were included in the
present review, consisting of 27 patients and 29 BRONJ
lesions (Tables 1, 2, 3, and 4).
Patient characteristics
The patients from this literature review ranged in age
from 55 to 79 yr and the mean age was 67 years.
Among the 22 patients whose age was reported, 17
(77.3%) were above 60 years old [6,8,10-12,14-16,18-21],
25 patients reported the gender and only one was male
[12] (Table 1). Furthermore, osteoporosis was the most
common co-morbidity observed in this review, being
present in 18 patients (66.6%) [4,9-11,14-16,18-21], fol-
lowed by hypertension (29.6%) [6,16,18-20] and diabetes
mellitus (14.8%) [8,15,20] (Table 1).
Characteristics of bisphosphonate treatment
Among the 24 patients that reported the use of BPs, 22
(91.6%) affirmed to use alendronate [4,6-9,11,12,15,
16,18-21], while 2 other patients were using ibandronate
[14] or risedronate [10] (Table 1). The mean duration of
BP therapy was 48 months, ranging from 6 months to 10
years, and most of the patients (73%) were using BPs for 3
or more years [4,6,9,12,15-17,19-21] (Table 1).
BRONJ characteristics
Most of the oral BRONJ cases in this literature review
were triggered by dental surgery procedures (51.7%),
such as tooth extraction and dental implants, observed
in 13 patients [4,5,7-9,12,14,17-20]. Of note, a large pro-
portion of BRONJ lesions appeared spontaneously
(41.38%) [9,10,12,13,15,19-21] (Table 2).
BRONJ lesions were located most commonly in the
lower jaw (72.4%), especially in the posterior area
[4,6,9,12-15,17,19,21]. The main signs and symptoms
reported in the studies included: bone exposure in 82% of
the lesions [4,6,7,9,11-18,20,21], followed by pain (78.5%)
[4,6,7,10-14,16-21], edema (35.7%) [6,7,10,12,15,17-19,21]
and purulent discharge (35.7%) [6,11,13-15,17,19,21].
Moreover, according to a staging system [9], 28 lesions
were diagnosed at stage II or III, and only one was at stage
I (Table 2). Furthermore, most of the patients (62.5%) pre-
sented a lytic pattern observed on image exams [4,12,
16-19,21], followed by bone sclerosis that was reported in
six patients (37.5%) [7,12,17,19,21].
Regarding the management of the BRONJ lesions, the
studies showed the treatment either by conservative
therapy alone (48%) [9,10,12,14,17,19,20] or associated
with surgical procedures (52%) [4,6,7,12,13,15-19,21].
The treatment only with conservative therapy was asso-
ciated with the most positiveo u t c o m e s ,i n c l u d i n gt h e
complete healing of the lesions (33.3%) [9,12], partial
and general positive results (58.3%) [10,14,19,20] and
only one patient presented a non-healed lesion (8.33%)
[17] (Table 4).
The association of conservative and surgical therapy
showed more diverse results, with complete healing in 3
lesions (25%) [13,21], partial and general positive results
(41.6%) [6,7,12,18,19] and 4 lesions were classified as
non-healed (33.4%) [4,6,15,17] (Table 4).
Discussion
Until the present moment, there is no randomized, con-
trolled, prospective clinical trial that assessed jaw osteo-
necrosis (ONJ) risk in patients with rheumatoid arthritis
who were using oral BPs. In the absence of this data,
the present paper performed a critical literature review
to investigate the current status of the epidemiological
aspects of patients with rheumatoid arthritis affected by
BRONJ.
Considering the prevalence of BRONJ lesions in
patients with RA, we considered only the raw number
of oral BRONJ reports in RA patients, since the accurate
number of non-neoplasic patients treated with oral BPs
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prevalence of BRONJ is extremely difficult but is possi-
ble to be estimated based on epidemiological studies.
Two reviews published recently, reporting patients
that presented BRONJ induced by the use of oral BPs,
observed a very low prevalence of these lesions in
patients with rheumatic diseases [22,23]. Other studies
reported that the BRONJ prevalence in patients treated
with oral BPs, ranges from 0.001% to 0.4% [17,24-27].
These numbers give the idea that the prevalence of
Table 1 Patients and Bisphosphonate Therapy Characteristics
Authors/Study Gender Age Comorbidities Medications (Years)
Marunick et al. [4] CS Patient 1 F 59 OST STE + METX + AL (3)
Yarom et al. [6] RS
Patient 2 F 73 HTN STE + METX + AL (7), infliximab
Patient 3 F 76 HTN + Arrhythmia + hypercholesterolemia AL (1.5)
Malden & Pai [7] CS Patient 4 F 56 NO STE + AL (1), leflunomide
Khamaisi et al. [8] RS Patient 5 F 73 DM AL (> 0,5)
Marx et al. [9] CS
Patient6 F NA OST STE + METX + AL (3.1)
Patient 7 F NA OST STE + METX + AL (6.3)
Patient 8 F NA OST STE + METX + AL (3.3)
Hamada [10] CR
Patient 9 F 68 OST STE + RISE (4)
Barrow [11] CR
Patient 10 F 70 OST STE + AL (< 3)
Junquera et al. [12] CS
Patient 12a/12b M 73 NO STE + METX + AL (3.8)
Mehanna et al. [13] CR
Patient 13 F 55 NO STE + Leflunomide + oral BPs (1)
Favia et al. [14] CS
Patient 14a/14b F 67 OST STE + IBAN (1)
Kwon et al. [15] CR
Patient 15 F 71 OST + DM STE + AL (3); OH
Sedghizadeh et al. [16] RS
Patient 16 F 63 OST + HTN STE + chemotherapy + AL (3)
Lo et al. [17] RS
Patient 17 NA NA NO oral BPs (4.8)
Patient 18 NA NA Hip Osteonecrosis STE + oral BPs (2.6)
Shin et al. [18] CR
Patient 19 F 67 OST + HTN AL (1) + HTN Drug
Park et al. [19] CS
Patient 20 F 68 OST STE + AL (5)
Patient 21 F 69 OST + PLE + TB STE + AL (10)
Patient 22 F 70 OST + HTN STE + AL (6)
Manfredi et al. [20] CS
Patient 23 F 68 OST + DM + HTN AL (4.25)
Patient 24 F 65 OST + HTN AL (5)
Patient 25 F 79 OST AL (4)
Patient 26 F 57 OST + DM + HTN AL (> 3)
Conte-Neto et al. [21] CR
Patient 27 F 58 NO AL (5)
Patient 28 F 68 OST STE + METX + AL (7)
CS Case series, RS Retrospective study, CR Case report, NA Not available
OST Osteoporosis, HTN Hypertension, DM, Diabetes Mellitus, GU gastric ulcer, PLE Pleuritis, TB Tuberculosis, STE Steroids, MTX Methotrexate; AL Alendronate, RISE
Risedronate, IBAN Ibandronate, OH oral hypoglycemiant
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Authors Trigger event Clinical features Stage Site
Marunick et al [4]
Patient 1 Extraction BE + pain + seqüestration II Md posterior lingual
Yarom et al [6]
Patient 2 Implants BE + pain + edema + PD + fistula + pathological fracture III Md posterior
Patient 3 Extraction BE + NHS + pain + edema + PD + fistula III Md posterior
Malden & Pai [7]
Patient 4 Extraction BE + pain + NHS + edema III Mx posterior
Khamaisi et al [8]
Patient 5 Dental surgery NA II Md
Marx et al [9]
Patient 6 Spontaneous BE I Md lingual
Patient 7 Palatal CT graft BE + erythema II Mx posterior palate
Patient 8 Spontaneous BE II Md posterior lingual
Hamada [10]
Patient 9 Spontaneous Pain + edema + sequestration II Md
Barrow [11]
Patient 10 Denture trauma BE + pain + PD + erythema II Mx palatine
Junquera et al [12]
Patient 12a Extraction BE + NHS + pain + hypoesthesia + erythema II Md anterior
Patient 12b Spontaneous BE + edema + trismus + pain + swelling II Md posterior lingual
Mehanna et al. [13]
Patient 13 Spontaneous BE + PD + trismus + abscess + pain II Md posterior
Favia et al. [14]
Patient 14a Extraction BE + pain + PD III Mx posterior
Patient 14b Extraction BE + pain + PD III Md posterior
Kwon et al. [15]
Patient 15 Spontaneous BE + PD + edema II Mx and Md posterior
Sedghizadeh et al [16]
Patient 16 Denture trauma BE + pain + infection II/III Mx
Lo et al [17]
Patient 17 Extraction BE + PD edema II Md posterior lingual
Patient 18 Extraction BE + pain + erythema II Mx posterior
Shin et al. [18]
Patient 19 Implants BE + pain + erythema + edema + increased probing depth II Mx posterior
Park et al [19]
Patient 20 Implants Pain + gingival bleeding + PI Pain II Md posterior
Patient 21 Extraction + PD + periodontitis II Mx posterior
Patient 22 Spontaneous Pain + itching sensation + edema III Md posterior and anterior
Manfredi et al. [20]
Patient 23 Spontaneous BE + pain + infection III Md
Patient 24 Spontaneous BE + pain + infection II Md
Patient 25 Spontaneous BE + pain + infection II Md
Patient 26 Extraction BE + pain + infection II Md
Conte-Neto et al. [21]
Patient 27 Spontaneous Pain + infection + increased probing depth + erythema II Md posterior
Patient 28 Spontaneous BE + pain + infection + edema + erythema + increased probing depth + PD II Md posterior
BE Bone exposure, PD purulent discharge, NHS non-healing socket, CT connective tissue, PI periimplantitis, Md mandible, Mx maxillae
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Authors Radiographic features Histologic features
Marunick et al. [4]
Patient 1 Osteolysis + sequestration Dense nonvital bone + subacutely inflamed granulation tissue
+ bacterial colonies
Yarom et al. [6]
Patient 2 ID CLP inflammatory infiltrate + increased vascularity + necrotic
bone + bacterial colonies (S. milleri)
Patient 3 ID CLP inflammatory infiltrate + increased vascularity + necrotic
bone + bacterial colonies (S. viridans)
Malden & Pai [7]
Patient 4 Thickening of the left sinus floor and bone density alteration
(suggestion of a retained root in the upper left second PM)
Sclerotic and necrotic bone
Khamaisi et al. [8]
Patient 5 NA NA
Marx et al. [9]
Patient 6 NA NA
Patient 7 NA NA
Patient 8 NA NA
Hamada [10]
Patient 9 NA NA
Barrow [11]
Patient 10 Widening of the PLS NA
Junquera et al.
[12]
Patient 12a Generalized lytic pattern of bone destruction with
superimposed sclerosis of the mandibular ramus
Necrotic osteitis + mixed infiltrate of lymphocytes and
granulocytes + medular fibrosis + numerous Actinomyces
colonies
Patient 12b
Mehanna et al.
[13]
Patient 13 Marked right neck collection with free gas and midline shift Normal skin flora with scanty diphtheroids
Favia et al. [14]
Patient 14a ID NA
Patient 14b ID NA
Kwon et al. [15]
Patient 15 Osteomyelitis characteristics NA
Sedghizadeh et al.
[16]
Patient 16 Ill-defined lytic lesion NA
Lo et al. [17]
Patient 17 Sequestration osteosclerosis, focal osteolysis with cortical
disruption
Actinomyces
Patient 18 Irregular area of bony sclerosis NA
Shin et al. [18]
Patient 19 Alveolar bone resorption with internal scattered residual bone
fragments, widening of LPS, and radiolucent lesion
NA
Park et al. [19]
Patient 20 Ill-defined lytic lesion Necrotic bone + acute and chronic non- specific inflammation
+ granulation formation
Patient 21 Ill-defined lytic lesion Necrotic bone
Patient 22 Ill-defined lytic lesion, mixed radiolucent and radiopaque
lesions
NONE
Manfredi et al.[20]
Patient 23
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Patient 24 NA NA
Patient 25
Patient 26
Conte-Neto et al.
[21]
Patient 27 Radiolucent lesions and sequestration Necrotic lamellar bone + chronic and acute inflammatory cells
+ bacterial colonies
Patient 28 Osteosclerosis and osteolysis NA
ID Impossible to determine, CLP chronic lympho-plasmacytic, NA not available, PLS periodontal ligament space, PM premolar
Table 4 Management and Outcomes of BRONJ Lesions in Patients with RA
Authors Management Outcomes
Marunick et al.
[4]
Patient 1 ATB + Oral Rinses and sequestrectomy No healing
Yarom et al. [6]
Patient 2 ATB and curettage + debridement +
resection
No healing
Patient 3 ATB and curettage + debridement +
resection
Partial healing
Malden & Pai
[7]
Patient 4 ATB + CLX + DD and debridement Progressive improvement
Khamaisi et al.
[8]
Patient 5 NA NA
Marx et al. [9]
Patient6 CLX + DD* Complete healing
Patient7 CLX + DD* Complete healing
Patient 8 CLX + DD* Complete healing
Hamada [10]
Patient 9 CT Partial Improvement
Barrow [11]
Patient 10 NA NA
Junquera et al.
[12]
Patient 12a ATB + CLX Complete healing
Patient 12b DD and sequestrectomy Remission of symptoms
Mehanna et al.
[13]
Patient 13 ATB + DD + drainage Complete healing
Favia et al. [14]
Patient 14a ATB + CLX + DD Partial Improvement
Patient 14b ATB + CLX + DD Partial Improvement
Kwon et al.
[15]
Patient 15 Sequestrectomy and CT and resection
and debridement + DD
Sequestrectomy: no healing. CT: complete healing in mx and no healing in Md.
Resection and debridement: healing after 6 months
Sedghizadeh et
al. [16]
Patient 16 ATB + CLX + DD + sequestrectomy +
debridement
NA
Lo et al. [17]
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quite low, however it should be considered that the pro-
portion of patients with rheumatic disease among all the
population sampled in these studies is probably reduced
as well.
At the same time, it is reasonable to expect an
increased tendency in the number of BRONJ lesions in
RA patients considering that there is a lack of knowl-
edge about this disease among rheumatologists in many
countries and that BPs are among the most frequent
prescribed drugs in rheumatologic practice [28]. This is
due to the high efficiency of BPs in the prevention and
treatment of osteoporosis, which is a common feature in
RA [29].
There is a considerable discussion in the literature
whether aging plays a significant role in BRONJ develop-
ment. Some studies found no statistically significant cor-
relation between aging and BRONJ [30,31]. Therefore,
the advanced age of the patients with BRONJ observed in
the studies [6,8,10-12,14-16,18-21] may reflect nothing
less than the increased BPs prescription to older patients
compared with younger ones, since osteoporosis and RA
are commonly seen in the elderly [29,32].
On the other hand, other authors include advanced
age as a BRONJ co-factor [19,33,34], which could be
related to the physiological effects of aging, including
inflammatory issues [35], immune dysfunction [36],
reduction of the blood flow and the remodeling ability
[37,38], and increased oxidative stress [39]. In fact, these
features are all implicated with BRONJ pathogenesis and
could explain why this disease is not reported in young
patients, even with other risk factors associated [40].
Paradoxically, BPs have been prescribed for the treat-
ment of steroid-induced osteonecrosis of the joints in
pediatric populations [41].
Controversial aspects have also been discussed regard-
ing gender as a BRONJ co-factor. Some studies found
no statistically significant correlation between gender
and BRONJ [33,34]. Therefore, we observed that the
large proportion of female patients from the studies
[4,6-11,13-16,18-21] can represent only a coincidence,
since women take oral BPs more frequently than males,
especially because RA and osteoporosis are more com-
mon in women [42].
In spite of that, other authors reported a positive cor-
relation between gender and BRONJ [19]. It has been
speculated that estrogen the r a p ym a yp l a yar o l ei nt h i s
correlation, since hormonal reposition has been asso-
ciated with an increased risk of BRONJ [43]. The con-
cern is that hormonal replacement therapy is likely to
occur in RA, since this disease is often worsened after
estrogen delivery [44]. In fact, the association of BPs
and estrogen reposition is especially possible in patients
with no satisfactory outcomes associated with a single
drug therapy or who have very low bone density with
multiple risks [45]. Moreover, treatment with estrogen/
bisphosphonate conjugate drugs has also been described
[46].
Table 4 Management and Outcomes of BRONJ Lesions in Patients with RA (Continued)
Patient 17 ATB + CLX + DD and sequestrectomy +
debridement
No healing
Patient 18 ATB + CLX + DD No healing
Shin et al. [18]
Patient 19 ATB + DD + CLX + debridement Satisfactory healing
Park et al. [19]
Patient 20 ATB + DD + CLX + curettage Satisfactory healing
Patient 21 ATB + DD + CLX + curettage NA
Patient 22 ATB + DD + CLX Satisfactory healing
Manfredi et al.
[20]
Patient 23 DD NA
Patient 24 DD + ATB + Laser Partial healing
Patient 25 ATB + Laser Partial healing
Patient 26 ATB Partial healing
Conte-Neto et
al. [21]
Patient 27 ATB + DD + CLX + sequestrectomy +
debridement
Complete healing
Patient 28 ATB + DD + CLX + curettage +
debridement
Complete healing
*It was not possible to determine which ATB was prescribed to these patients
ATB antibiotic therapy, CLX chlorhexidine, DD drug discontinuation, CT conservative treatment, NA not available
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prevalent co-morbidity observed in the studies
[4,9-11,14-16,18-21], since t h i si sac o m m o nf e a t u r ei n
RA patients for several reasons, including: (a) post-
menopausal women represent part of the main risk
group for RA and are at risk for accentuated bone loss;
(b) steroid therapy is often prescribed for the treatment
of RA; (c) physical inactivity is characteristic of RA due
to disease activity; and (d) bone loss due to inflamma-
tory disease mechanisms, such as elevated levels of sys-
temic cytokines [29].
It has been shown that there is a direct relation
between BRONJ occurrence and BPs potency [13,33],
which is supported by the high incidence of BRONJ in
patients receiving intravenous BPs [47], as well as by fas-
ter lesion onset in these patients [24]. This assumption
corroborates with the higher incidence of BRONJ in
patients using alendronate, as seen in the studies revised
here [4,6-9,11,12,15,16,18-21], since it is the most potent
drug among the BPs [9].
In contrast, Kos and Luczak [48] found no correlation
between the type of BPs and BRONJ incidence, which
reinforces the assumption that it can be only a coinci-
dence. In fact, over the last decade, alendronate was
among the most used drugs in the USA as first-line ther-
apy for the prevention or treatment of osteoporosis [49],
both in non-neoplasic BRONJ patients without RA
[6,9,14,16] and in patients with RA [32]. Furthermore, it
is reasonable to understand why ibandronate, a potent
nitrogen-containing bisphosphonate (N-BPs) [7] that is
much less prescribed compared with alendronate, is not
associated with large-series cases of BRONJ [23].
It has been discussed that one of the most critical factors
for BRONJ is the duration of oral BPs therapy [9,33]. It is
believed that there is an increased incidence of oral
BRONJ in patients treated with oral BPs for more than 3
years [5,9], which is in agreement with the findings of the
studies revised here [4,6,9,12,15-17,19-21]. In fact, longer-
term use of oral BPs may have a dose-equivalence effect,
potentially approximating BPs levels in bone thought to be
achieved only through high-dose intravenous delivery [16],
and the total dose administered over a long period of time
is important for the magnitude of the bone turnover
reduction [50].
An interesting observation is that it has been suggested
a trend of early-onset lesions due to steroids therapy [9].
However, this tendency was not confirmed in the patients
of the studies revised in this paper, since the mean dura-
tion of BP therapy in steroid-treated patients was similar
to patients that have not been treated with this drug.
Furthermore, some authors reported early-onset lesions
in patients with RA and no history of steroids [3,19].
The literature indicates a strong association of BRONJ
with dental surgical procedures in all groups of patients
[3,5,9]. Although we also observed this tendency in the
large number of lesions triggered by teeth extractions
and dental implants in the studies that were retrieved
[4,5,7-9,12,14,17-20], it is relevant to state that sponta-
neous occurrence of BRONJ lesions was observed in a
significant proportion of individuals in several studies
[9,10,12,13,15,19-21].
Most of the lesions in the studies were diagnosed in
lower jaw at stage II or III [4,6-21] with the most common
clinical findings being bone exposure, pain, edema, and
purulent discharge. In fact, it also represents the same
clinical aspects found in patients with no RA [6,9,14,16].
This evidence brings to light the lack of knowledge and
attention about early clinical features that include non-
specific signs and symptoms in the oral cavity, including
no clinical evidence of bone exposure. The concern is that
lesions can progress rapidly, and, in advanced stages, par-
esthesia, fistula formation, and pathologic fracture can also
occur, even in RA patients [6].
The typical imaging finding in all groups of patients with
BRONJ is the association of osteolysis and sclerosis
aspects. Within this context, when it is considered that
bone sclerosis is often detected in the initial stages of
BRONJ [51], this sign can also be maintained in advanced
stages; indeed, we observed in the studies that bone sclero-
sis was reported in six patients, all classified in advanced
stages [7,12,17,19,21]. Therefore, a careful dental examina-
tion could allow an early diagnosis and intervention and
assist the patients in responding more promptly to stage-
specific treatment regimens for BRONJ.
Regarding the management and outcomes of BRONJ
lesions in patients with RA, there is no widely accepted
treatment protocol to BRONJ. Some authors believe
that surgical procedures are not effective in patients
with BRONJ and have led to further bone exposure,
worsening of symptoms, and a greater risk of pathologic
fracture, indicating conservative approaches as the best
choice, including antibiotics, oral rinses with chlorhexi-
dine, and ‘drug holidays’[47]. In contrast, other authors
believe that surgical procedures may achieve better out-
comes in non-neoplasic patients [14].
In the papers that we revised, the lesions were treated
either by conservative therapy (48%) or its association with
surgical procedures (52%). Overall, this literature review
showed that most of the lesions were treated with conser-
vative approach [9,10,12,14,17,19,20] and were associated
with the most positive outcomes including the complete
healing of the lesions (33.3%) and no healing in only one
patient (8.33%) [17] (Table 4). However, in other studies
[4,6,7,12,13,15-19,21] the association of conservative and
surgical therapy showed more diverse outcomes, with
complete healing in only three lesions (25%) [13,21].
In fact, the management of BRONJ lesions is a great
challenge, which reinforces the necessity of an adequate
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and motivation of the patients to adopt preventive mea-
sures in order to maintain a good oral hygiene and [52].
Conclusion
The main characteristics of BRONJ patients with RA are
generally similar to those with no RA. This critical
review highlights a serious concern regarding the
delayed diagnosis of BRONJ lesions, since most of these
patients were diagnosed in stage II/III. It is clear that
the rheumatologist needs to be aware of the potential
risk of their patients developing BRONJ and must work
together with the dentist to prevent and detect the
lesions as soon as possible.
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